Aliskiren/hydrochlorothiazide

Aliskiren/hydrochlorothiazide
Combination of
AliskirenRenin inhibitor
HydrochlorothiazideDiuretic
Clinical data
Trade namesTekturna HCT, Rasilez HCT, others
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Aliskiren/hydrochlorothiazide, sold under the brand name Tekturna HCT among others, is a fixed-dose combination medication for the treatment of hypertension (high blood pressure).[1][2] It contains aliskiren, a renin inhibitor, and hydrochlorothiazide, a diuretic.[1][2] It is taken by mouth.[1]

The most common side effect is diarrhea.[2]

Aliskiren/hydrochlorothiazide was approved for medical use in the United States in January 2008,[3] and for use in the European Union in January 2009.[2]

Medical uses

Aliskiren/hydrochlorothiazide is indicated for the treatment of essential hypertension in adults.[2]

References

  1. 1 2 3 4 "Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated". DailyMed. 7 January 2020. Retrieved 26 August 2020.
  2. 1 2 3 4 5 6 "Rasilez HCT EPAR". European Medicines Agency. Retrieved 27 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. "Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 27 August 2020.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.